Skip to main content
Premium Trial:

Request an Annual Quote

Promega Asks Court to Stop Benitec from Licensing RNAi Technology

NEW YORK, Nov. 11 (GenomeWeb News) - Promega has filed a motion with the US District Court of Delaware seeking an injunction to stop Benitec from granting further licenses to ddRNAi technology to which it claims exclusivity.

The motion is the latest move in row between the two companies over rights to the RNAi technology. In July, Benitec sued Promega, which had acquired the exclusive rights to use and sublicense the ddRNAi technology in areas outside human therapeutics in exchange for $350,000 and royalties.

The suit claims that Promega had failed to meet its payment requirements to Benitec, and therefore had forfeited its exclusive rights to the technology in lieu of a non-exclusive license to simply use the technology.

Promega's motion follows Benitec's announcment in October that it had granted Artemis Pharmaceuticals of Cologne, Germany, a non-exclusive commercial license to use Benitec's ddRNAi technology.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.